|

Belzutifan Clinical Trials

10 actively recruiting trials across 7 locations

Also known as: 3-(((1S,2S,3R)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile, C17H12F3NO4S, MK-6482, MK-6482, PT2977, WELIREG, NSC#825217 +5 more

Pipeline

Phase 1: 2Phase 2: 5Phase 3: 2Phase 1/2: 1

Top Sponsors

  • Merck Sharp & Dohme LLC5
  • NYU Langone Health1
  • M.D. Anderson Cancer Center1
  • José Claudio Casali da Rocha1
  • HiberCell, Inc.1

Indications

  • Cancer10
  • Von Hippel-Lindau Disease3
  • Renal Cell Carcinoma3
  • Pheochromocytoma/Paraganglioma2
  • Endolymphatic Sac Tumor1

Other3 trials

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Phase 3
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Phase 3
Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial
Phase 2

Goodyear, Arizona1 trial

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

City of Hope - Phoenix ( Site 0006)

Phase 2

Tucson, Arizona1 trial

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

University of Arizona Cancer Center

Phase 1

Los Angeles, California1 trial

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Cedars-Sinai Medical Center ( Site 0110)

Phase 2

San Francisco, California1 trial

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

UCSF Medical Center at Mission Bay ( Site 5008)

Phase 1/2

Boston, Massachusetts1 trial

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

Brigham and Women's Hospital

Phase 2

New York, New York1 trial

Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)

NYU Langone Health

Phase 1

Houston, Texas1 trial

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

The University of Texas M. D. Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.